Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 4
2013 3
2014 5
2015 5
2016 8
2017 4
2018 9
2019 5
2020 13
2021 12
2022 19
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Villanueva-Bueno C, Escudero-Vilaplana V, Collado-Borrell R, Giménez-Manzorro Á, Ribed A, Marzal-Alfaro B, Revuelta-Herrero JL, Gonzalez-Haba E, Herranz A, Sanjurjo M. Villanueva-Bueno C, et al. Among authors: escudero vilaplana v. Expert Opin Drug Saf. 2022 Jan;21(1):107-119. doi: 10.1080/14740338.2021.1965990. Epub 2021 Aug 12. Expert Opin Drug Saf. 2022. PMID: 34357828 Review.
Pazopanib-Associated Transient Ischemic Attack.
Revuelta-Herrero JL, Escudero-Vilaplana V, Álvarez-Álvarez R, Sanjurjo-Sáez M. Revuelta-Herrero JL, et al. Among authors: escudero vilaplana v. Am J Ther. 2018 May/Jun;25(3):e393-e394. doi: 10.1097/MJT.0000000000000710. Am J Ther. 2018. PMID: 29424756 No abstract available.
Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors.
García-Martín E, Romero-Jiménez RM, Baniandrés-Rodríguez O, Escudero-Vilaplana V, Benedí-González J, de Los Ríos Luna PM, Herranz-Alonso A, Sanjurjo-Sáez M. García-Martín E, et al. Among authors: escudero vilaplana v. Eur J Hosp Pharm. 2023 Apr 24:ejhpharm-2022-003594. doi: 10.1136/ejhpharm-2022-003594. Online ahead of print. Eur J Hosp Pharm. 2023. PMID: 37094886
Eosinophilia secondary to lenalidomide therapy.
Escudero-Vilaplana V, Osorio-Prendes S, Collado-Borrell R, González-Arias E, Sanjurjo-Sáez M. Escudero-Vilaplana V, et al. J Clin Pharm Ther. 2018 Apr;43(2):273-275. doi: 10.1111/jcpt.12611. Epub 2017 Aug 17. J Clin Pharm Ther. 2018. PMID: 28833364
Mobile Apps for Hematological Conditions: Review and Content Analysis Using the Mobile App Rating Scale.
Narrillos-Moraza Á, Gómez-Martínez-Sagrera P, Amor-García MÁ, Escudero-Vilaplana V, Collado-Borrell R, Villanueva-Bueno C, Gómez-Centurión I, Herranz-Alonso A, Sanjurjo-Sáez M. Narrillos-Moraza Á, et al. Among authors: escudero vilaplana v. JMIR Mhealth Uhealth. 2022 Feb 16;10(2):e32826. doi: 10.2196/32826. JMIR Mhealth Uhealth. 2022. PMID: 35171109 Free PMC article. Review.
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Escudero-Vilaplana V, Collado-Borrell R, De Castro J, Insa A, Martínez A, Fernández E, Sullivan I, Flores A, Arrabal N, Carcedo D, Manzaneque A. Escudero-Vilaplana V, et al. J Med Econ. 2023 Jan-Dec;26(1):445-453. doi: 10.1080/13696998.2023.2188844. J Med Econ. 2023. PMID: 36883193 Free article.
Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities.
González J, Quiroga M, Escudero-Vilaplana V, Collado-Borrell R, Herranz-Alonso A, Sanjurjo Sáez M. González J, et al. Among authors: escudero vilaplana v. Expert Opin Drug Saf. 2018 Jun;17(6):553-572. doi: 10.1080/14740338.2018.1477937. Epub 2018 May 28. Expert Opin Drug Saf. 2018. PMID: 29781751 Review.
Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease.
Hoyo-Muñoz A, Collado-Borrell R, Escudero-Vilaplana V, Bastos-Oreiro M, Herranz-Alonso A, Sanjurjo-Sáez M. Hoyo-Muñoz A, et al. Among authors: escudero vilaplana v. J Clin Pharm Ther. 2022 Apr;47(4):548-551. doi: 10.1111/jcpt.13513. Epub 2021 Sep 12. J Clin Pharm Ther. 2022. PMID: 34514634
75 results